Aldosterone breakthrough during RAS blockade: A role for endothelins and their antagonists?

Current Hypertension Reports

Volumn 8, Issue 3, 2006, Pages 262-268

  Rossi, Gian Paolo ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGITALIS; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN DERIVATIVE; ENDOTHELIN RECEPTOR ANTAGONIST; ENDOTHELIN[1-31]; EPLERENONE; LOOP DIURETIC AGENT; LOSARTAN; POTASSIUM; SPIRONOLACTONE; UNCLASSIFIED DRUG; VERAPAMIL;

ACUTE HEART INFARCTION; ADRENAL CORTEX; ALDOSTERONE RELEASE; ATRIOVENTRICULAR BLOCK; AUTOCRINE EFFECT; CLINICAL TRIAL; ENDOTHELIUM LESION; GYNECOMASTIA; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; IMPOTENCE; PARACRINE SIGNALING; PRIMARY HYPERALDOSTERONISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VASCULAR ENDOTHELIUM; ZONA GLOMERULOSA;

ADRENAL CORTEX; ALDOSTERONE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ENDOTHELIN-1; HEART FAILURE; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, ENDOTHELIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 33744956091     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-006-0060-5     Document Type: Review

References (80)

1. Genest J, Lemieux G, Davignon A, et al.: Human arterial hypertension: A state of mild chronic hyperaldosteronism? Science 1956, 123:503-505.
2. Weinberger MH, Roniker B, Krause SL, Weiss RJ: Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 2002, 15:709-716.
3. Pitt B, Reichek N, Willenbrock R, et al.: Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-Left Ventricular Hypertrophy Study. Circulation 2003, 108:1831-1838.
4. Stowasser M: New perspectives on the role of aldosterone excess in cardiovascular disease. Clin Exp Pharmacol Physiol 2001, 28:783-791.
5. Rossi GP: Primary aldosteronism: A needle in a haystack or a yellow cab on Fifth Avenue? Curr Hypertens Rep. 2004, 6:1-4.
6. Rossi GP, Bernini G, Fabris B, et al.: Primary aldosteronism (PA) prevalence in Italy (PAPY) study: Results of a nationwide survey. Am J Hypertens 2005, 18:S235A.
7. Swedberg K, Eneroth P, Kjekshus J, Snapinn S: Effects of enalapril and neuroendocrine activation on prognosis in severe congestive heart failure (follow-up of the CONSENSUS trial). CONSENSUS Trial Study Group. Am J Cardiol 1990, 66:40D-44D.
8. Swedberg K, Kjekshus J, Snapinn S: Long-term survival in severe heart failure in patients treated with enalapril. Ten year follow-up of CONSENSUS I. Eur Heart J 1999, 20:136-139.
9. Dahlof B, Devereux RB, Kjeldsen SE, et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995-1003.
10. Cohen SA, Jondeau G, Beauvais F, Berdeaux A: Beneficial effects of carvedilol on angiotensin-converting enzyme activity and renin plasma levels in patients with chronic heart failure. Eur J Heart Fail. 2004, 6:463-466.
11. Zannad F: Aldosterone and heart failure. Eur Heart J 1995, 16:98-102.
12. Masson S, Latini R, Bevilacqua M, et al.: Within-patient variability of hormone and cytokine concentrations in heart failure. Pharmacol Res 1998, 37:213-217.
13. Rossi GP, Boscaro M, Ronconi V, Funder JW: Aldosterone as a cardiovascular risk factor. Trends Endocrinol Metab 2005, 16:104-107.
14. Brilla CG, Maisch B, Weber KT: Myocardial collagen matrix remodelling in arterial hypertension. Eur Heart J 1992, 13:24-32.
15. Brilla CG, Pick R, Tan LB, et al.: Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 1990, 67:1355-1364.
16. Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709-717.
17. Pitt B, Remme W, Zannad F, et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309-1321.
18. Silvestre JS, Heymes C, Oubenaissa A, et al.: Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 1999, 99:2694-2701.
19. Delcayre C, Silvestre JS, Garnier A, et al.: Cardiac aldosterone production and ventricular remodeling. Kidney Int 2000, 57:1346-1351.
20. Gomez-Sanchez CE, Gomez-Sanchez EP: Cardiac steroidogenesis - new sites of synthesis, or much ado about nothing? J Clin Endocrinol Metab 2001, 86:5118-5120.
21. Bonvalet JP, Alfaidy N, Farman N, Lombes M: Aldosterone: intracellular receptors in human heart. Eur Heart J 1995, 16:92-97.
22. Weber KT, Sun Y, Guarda E: Structural remodeling in hypertensive heart disease and the role of hormones. Hypertension 1994, 23:869-877.
23. Park JB, Schiffrin EL: Cardiac and vascular fibrosis and hypertrophy in aldosterone-infused rats: role of endothelin-1. Am J Hypertens 2002, 15:164-169.
24. Robert V, Heymes C, Silvestre JS, et al.: Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis. Hypertension 1999, 33:981-986.
25. Rossi GP, Sacchetto A, Visentin P, et al.: Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension 1996, 27:1039-1045.
26. Rossi GP, Sacchetto A, Pavan E, et al.: Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma. Circulation 1997, 95:1471-1478.
27. Rossi GP: Aldosterone excess and left ventricular hypertrophy. Am J Hyertens 2006, In press.
28. Rossi GP, Di Bello V, Ganzaroli C, et al.: Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism. Hypertension 2002, 40:23-27.
29. Takeda Y, Miyamori I, Yoneda T et al.: Production of aldosterone in isolated rat blood vessels. Hypertension 1995, 25:170-173.
30. Hatakeyama H, Miyamori I, Fujita T et al.: Vascular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. J Biol Chem 1994, 269:24316-24320.
31. Hatakeyama H, Miyamori I, Takeda Y, et al.: The expression of steroidogenic enzyme genes in human vascular cells. Biochem Mol Biol Int. 1996, 40:639-645.
32. Funder JW, Pearce PT, Smith R, Campbell J: Vascular type I aldosterone binding sites are physiological mineralocorticoid receptors. Endocrinology 1989, 125:2224-2226.
33. Weber KT, Brilla CG: Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991, 83:1849-1865.
34. Young M, Fullerton M, Dilley R, Funder J: Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest 1994, 93:2578-2583.
35. Virdis A, Neves MF, Amiri F, et al.: Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 2002, 40:504-510.
36. Rocha R, Chander PN, Khanna K, et al.: Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998, 31:451-458.
37. Rocha R, Martin-Berger CL, Yang P, et al.: Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology 2002, 143:4828-4836.
38. Rocha R, Rudolph AE, Frierdich GE, et al.: Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002, 283: H1802-H1810.
39. Rizzoni D, Porteri E, Castellano M, et al.: Vascular hypertrophy and remodeling in secondary hypertension. Hypertension 1996, 28:785-790.
40. Rizzoni D, Porteri E, Castellano M, et al.: Endothelial dysfunction in hypertension is independent from the etiology and from vascular structure. Hypertension 1998, 31:335-341.
41. Farquharson CAJ, Struthers AD: Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000, 101:594-597.
42. Garnier A, Bendall JK, Fuchs S, et al.: Cardiac specific increase in aldosterone production induces coronary dysfunction in aldosterone synthase-transgenic mice. Circulation 2004, 110:1819-1825.
43. Pu Q, Neves MF, Virdis A, et al.: Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling. Hypertension 2003, 42:49-55.
44. Liu SL, Schmuck S, Chorazcyzewski JZ, et al.: Aldosterone regulates vascular reactivity: short-term effects mediated by phosphatidylinositol 3-kinase-dependent nitric oxide synthase activation. Circulation 2003, 108:2400-2406.
45. Oberleithner H, Ludwig T, Riethmuller C, et al.: Human endothelium: target for aldosterone. Hypertension 2004, 43:952-956.
46. Brunner H, Cockcroft JR, Deanfield J, et al.: Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005, 23:233-246.
47. Ammarguellat F, Larouche II, Schiffrin EL: Myocardial fibrosis in DOCA-salt hypertensive rats: effect of endothelin ET(A) receptor antagonism. Circulation 2001, 103:319-324.
48. Park JB, Schiffrin EL: ET(A) receptor antagonist prevents blood pressure elevation and vascular remodeling in aldosterone-infused rats. Hypertension 2001, 37:1444-1449.
49. Deng LY, Day R, Schiffrin EL: Localization of sites of enhanced expression of endothelin-1 in the kidney of DOCA-salt hypertensive rats. J Am Soc Nephrol 1996, 7:1158-1164.
50. Lariviere R, Thibault G, Schiffrin EL: Increased endothelin-1 content in blood vessels of deoxycorticosterone acetate-salt hypertensive but not in spontaneously hypertensive rats. Hypertension 1993, 21:294-300.
51. Rossi GP, Sacchetto A, Cesari M, Pessina AC: Interactions between endothelin-1 and the renin-angiotensin-aldosterone system. Cardiovasc Res 1999, 43:300-307.
52. Schiffrin EL: Endothelin: role in experimental hypertension. J Cardiovasc Pharmacol 2000, 35:S33-S35.
53. Funder JW: Is aldosterone bad for the heart? Trends Endocrinol Metab 2004, 15:139-142.
54. Nussdorfer GG, Rossi GP, Malendowicz LK, Mazzocchi G: Autocrine-paracrine endothelin system in the physiology and pathology of steroid-secreting tissues. Pharmacol Rev 1999, 51:1-35.
55. Rossi G, Albertin G, Belloni A, et al.: Gene expression, localization, and characterization of endothelin A and B receptors in the human adrenal cortex. J Clin Invest 1994, 94:1226-1234.
56. Rossi GP, Belloni AS, Nussdorfer GG, Pessina AC: Endothelin-1 and the adrenal gland. J Cardiovasc Pharmacol 2000, 35:18-20.
57. Delarue C, Conlon JM, Remy-Jouet I, et al.: Endothelins as local activators of adrenocortical cells. J Mol Endocrinol 2004, 32:1-7.
58. Iwanaga Y, Kihara Y, Hasegawa K, et al.: Cardiac endothelin-1 plays a critical role in the functional deterioration of left ventricles during the transition from compensatory hypertrophy to congestive heart failure in salt-sensitive hypertensive rats. Circulation 1998, 98:2065-2073.
59. Kaburagi S, Hasegawa K, Morimoto T, et al.: The role of endothelin-converting enzyme-1 in the development of alpha1-adrenergic-stimulated hypertrophy in cultured neonatal rat cardiac myocytes. Circulation 1999, 99:292-298.
60. Wei CM, Lerman A, Rodeheffer RJ, et al.: Endothelin in human congestive heart failure. Circulation 1994, 89:1580-1586.
61. Pacher R, Bergler-Klein J, Globits S, et al.: Plasma big endothelin-1 concentrations in congestive heart failure patients with or without systemic hypertension. Am J Cardiol 1993, 71:1293-1299.
62. Sutsch G, Bertel O, Kiowski W: Acute and short-term effects of the nonpeptide endothelin-1 receptor antagonist bosentan in humans. Cardiovasc Drugs Ther 1997, 10:717-725.
63. Sutsch G, Kiowski W, Yan XW, et al.: Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation 1998, 98:2262-2268.
64. Rossi GP, Albertin G, Bova S, et al.: Autocrine-paracrine role of endothelin-1 in the regulation of aldosterone synthase expression and intracellular Ca2+ in human adrenocortical carcinoma. Endocrinology 1997,138:4421-4426.
65. Rossi GP, Ganzaroli C, Cesari M, et al.: Endothelin receptor blockade lowers plasma aldosterone levels via different mechanisms in primary aldosteronism and high-to-normal renin hypertension. Cardiovasc Res 2003, 57:277-283.
66. Andreis PG, Neri G, Tortorella C, et al.: Mechanisms transducing the aldosterone secretagogue signal of endothelins in the human adrenal cortex. Peptides 2002, 23:561-566.
67. Fraccarollo D, Hu K, Galuppo P, et al.: Chronic endothelin receptor blockade attenuates progressive ventricular dilation and improves cardiac function in rats with myocardial infarction: possible involvement of myocardial endothelin system in ventricular remodeling. Circulation 1997, 96:3963-3973.
68. Mulder P, Richard V, Derumeaux G, et al.: Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation 1997, 96:1976-1982.
69. Kiowski W, Sutsch G, Hunziker P, et al.: Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet 1995, 346:732-736.
70. Sutsch G, Kiowski W: Endothelin and endothelin receptor antagonism in heart failure. J Cardiovasc Pharmacol 2000, 35:S69-S73.
71. Torre-Amione G, Young JB, Durand J, et al.: Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure. Circulation 2001, 103:973-980.
72. Torre-Amione G, Durand JB, Nagueh S, et al.: A pilot safety trial of prolonged (48 h) infusion of the dual endothelin-receptor antagonist tezosentan in patients with advanced heart failure. Chest 2001, 120:460-466.
73. Torre-Amione G, Young JB, Colucci WS, et al.: Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2003, 42:140-147.
74. Luscher TF, Enseleit F, Pacher R, et al.: Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT). Circulation 2002, 106:2666-2672.
75. Anand I, McMurray J, Cohn JN, et al.: Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet 2004, 364:347-354.
76. Rich S, McLaughlin VV: Endothelin receptor blockers in cardiovascular disease. Circulation 2003, 108:2184-2190.
77. Ding SS, Qiu C, Hess P, et al.: Chronic endothelin receptor blockade prevents renal vasoconstriction and sodium retention in rats with chronic heart failure. Cardiovasc Res 2002, 53:963-970.
78. Mazzocchi G, Rossi GP, Rebuffat P, et al.: Endothelin-1 stimulates deoxyribonucleic acid synthesis and cell proliferation in rat adrenal zona glomerulosa, acting through an endothelin A receptor coupled with protein kinase C- and tyrosine kinase-dependent signaling pathways. Endocrinology 1997, 138:2333-2338.
79. Urata H, Ganten D: Cardiac angiotensin II formation: the angiotensin-I converting enzyme and human chymase. Eur Heart J 1993, 14:177-182.
80. Rossi GP, Andreis PG, Colonna S, et al.: Endothelin-1[1-31]: a novel autocrine-paracrine regulator of human adrenal cortex secretion and growth. J Clin Endocrinol Metab 2002, 87:322-328.